Triple negative breast cancer - current status and prospective targeted treatment based on her1 (EGFR), TOP2A and C-MYC gene assessment

Biomedical Papers

Volumn 153, Issue 1, 2009, Pages 13-18

  Bouchalova, Katerina ^a   Cizkova, Magdalena ^a   Cwiertka, Karel ^a   Trojanec, Radek ^a   Hajduch, Marian ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Biological therapy; C MYC; EGFR(HER1); Targeted therapy; TOP2A; Triple negative breast cancer

Indexed keywords

DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; OXIME; PROGESTERONE RECEPTOR; TECHNETIUM COMPLEX; TECHNETIUM TC 99M 4,9 DIAZA 3,3,10,10 TETRAMETHYLDODECAN 2,11 DIONE DIOXIME; TECHNETIUM TC 99M 4,9-DIAZA-3,3,10,10-TETRAMETHYLDODECAN-2,11-DIONE DIOXIME; TUMOR ANTIGEN;

ARTICLE; BREAST TUMOR; CHEMISTRY; DRUG RESISTANCE; FEMALE; GENETICS; HUMAN; ONCOGENE MYC;

ANTIGENS, NEOPLASM; BREAST NEOPLASMS; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, MYC; HUMANS; ORGANOTECHNETIUM COMPOUNDS; OXIMES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 70149088984     PISSN: 12138118     EISSN: 12138118     Source Type: Journal    
DOI: 10.5507/bp.2009.002     Document Type: Article

References (66)

1. 1. www.svod.cz.
2. 2. www.uzis.cz.
3. Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology 2008;52:108-18.
4. Tavassoli FA, Devilee P. World health organization classification of tumors. Pathology and genetics of tumours of the breast and female genital organs. IARC Press: Lyon; 2003.
5. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. PNAS 2003;100:8418-23.
6. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-5374.
7. Shiu KK, Tan DS, Reis-Filho JS. Development of therapeutic approaches to 'triple negative' phenotype breast cancer. Expert Opin Ther Targets 2008;12:1123-37.
8. Tumors of the Breast. In: Heim S, Mitelman F, editors. Cancer Cytogenetics. New York: Wiley-Liss; 1995, p. 369-388.
9. Struski S, Doco-Fenzy M, Cornillet-Lefebvre P. Compilation of published comparative genomic hybridization studies. Cancer Genet Cytogenet 2002;135,63-90.
10. Pritchard KI. Adjuvant therapy of the very young woman. Breast 2007;16 Suppl 2:136-46.
11. Pritchard KI. Adjuvant therapy for breast cancer: we are solving the puzzle, but pieces are still missing. JNCI 2007;99:494-5.
12. Järvinen TA, Tanner M, Rantanen V, Bärlund M, Borg A, Grénman S et al. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000;156:839-847.
13. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. NEJM 2001;344(11):783-792.
14. Wang S, Saboorian MH, Frenkel E, Hynan L, Gokaslan ST, Ashfaq R. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol 2000;53:374-81.
15. Perez EA, Roche PC, Jenkins RB, Reynolds CA, Halling KC, Ingle JN et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc 2002;77:148-54.
16. Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. JNCI 2002;94:855-7.
17. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5:341-54.
18. Filardo EJ, Quinn JA, Sabo E. Association of the membrane estrogen receptor, GPR30, with breast tumor metastasis and transactivation of the epidermal growth factor receptor. Steroids. 2008;73:870-5.
19. Agrawal A, Gutteridge E, Gee JM, Nicholson RI, Robertson JF. Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocr Relat Cancer. 2005;12:S135-44.
20. Hobday TJ, Perez EA. Molecularly targeted therapies for breast cancer. Cancer Control 2005;12.73-81.
21. Reis-Filho JS, Milanezi F, Carvalho S, Simpson PT, Steele D, Savage K et al. Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. Breast Cancer Res 2005;7:R1028-35.
22. Siziopikou KP, Ariga R, Proussaloglou KE, Gattuso P, Cobleigh M. The challenging estrogen receptor-negative/ progesterone receptor-negative/HER-2-negative patient: a promising candidate for epidermal growth factor receptor-targeted therapy? Breast J 2006;12,360-2.
23. Siziopikou KP, Cobleigh M. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast 2007;16,104-7.
24. Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H et al. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 2004;64,8534-40.
25. Tan DS, Marchió C, Jones RL, Savage K, Smith IE, Dowsett M et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 2008;111:27-44.
26. Reis-Filho JS, Pinheiro C, Lambros MB, Milanezi F, Carvalho S, Savage K et al. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol 2006;209:445-53.
27. www.clinicaltrials.gov.
28. Bouchalová K, Trojanec R, Kolár Z, Cwiertka K, Cernáková I, Mihál V et al. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer. Neoplasma 2006;53,393-401.
29. Järvinen TA, Liu ET. Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes--molecular basis for combination chemotherapy in cancer. Curr Cancer Drug Targets 2006;6:579-602.
30. Keith WN, Douglas F, Wishart GC, McCallum HM, George WD, Kaye SB et al. Co-amplification of erbB2, topoisomerase II alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase I on chromosome 20. Eur J Cancer 1993;29A,1469-75.
31. Smith K, Houlbrook S, Greenall M, Carmichael J, Harris AL. Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. Oncogene 1993;8,933-8.
32. Watt PM, Hickson ID. Structure and function of type II DNA topoisomerases. Biochem J 1994;303,681-95.
33. Wosikowski K, Schuurhuis D, Kops GJ, Saceda M, Bates SE. Altered gene expression in drug-resistant human breast cancer cells. Clin Cancer Res 1997;3,2405-14.
34. Harris LN, Yang L, Tang C, Yang D, Lupu R. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2. Clin Cancer Res 1998;4,1005-12.
35. Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005;23: 7483-90.
36. Arriola E, Rodriguez-Pinilla SM, Lambros MB, Jones RL, James M, Savage K et al. Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res Treat 2007;106:181-9.
37. Usha L, Tabesh B, Morrison LE, Rao RD, Jacobson K, Zhu A et al. Topoisomerase II alpha gene copy loss has adverse prognostic significance in ERBB2-amplified breast cancer: a retrospective study of paraffin-embedded tumor specimens and medical charts. J Hematol Oncol 2008;1:12Epub ahead of print.
38. Burgess DJ, Doles J, Zender L, Xue W, Ma B, McCombie WR et al. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci U S A 2008;105:9053-8.
39. Mueller RE, Parkes RK, Andrulis I, O'Malley FP. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Genes Chromos Cancer 2004;39,288-97.
40. Hajduch M, Palacova M, Trojanec R, Dusek L, Petrakova K, Spackova K et al. Anthracycline based chemotherapy decreases amplification status of Her-2/neu and topoisomerase II alpha genes in locally advanced breast cancer. ASCO, 40th Annual Meeting, June 5-8, 2004, New Orleans, LA. Abstract 9521 in J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004; 22(14S).
41. Bofin AM, Ytterhus B, Hagmar BM. TOP2A and HER-2 gene amplification in fine needle aspirates from breast carcinomas. Cytopathology 2003;14:314-9.
42. Hagen AI, Bofin AM, Ytterhus B, Maehle LO, Kjellevold KH, Myhre HO et al. Amplification of TOP2A and HER-2 genes in breast cancers occurring in patients harbouring BRCA1 germline mutations. Acta Oncol 2007;46:199-203.
43. Nielsen KV, Ejlertsen B, Møller S, Jørgensen JT, Knoop A, Knudsen H et al. The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D. Acta Oncol 2008;47:725-34.
44. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13,2329-34.
45. Weigelt B, Kreike B, Reis-Filho JS. Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res Treat. 2008Epub ahead of print.
46. Nass SJ, Dickson RB. Defining a role for c-Myc in breast tumorigenesis. Breast Cancer Res Treat 1997;44:1-22.
47. Dang CV, Resar LM, Emison E, Kim S, Li Q, Prescott JE et al. Function of the c-Myc oncogenic transcription factor. Experimental Cell Research 1999;253:63-77.
48. Lee CM, Reddy EP. The v-myc oncogene. Oncogene 1999;18:2997-3003.
49. Prendergast GC. Mechanisms of apoptosis by c-Myc. Oncogene 1999;18:2967-87.
50. Schmidt EV. The role of c-myc in cellular growth control. Oncogene 1999;18:2988-96.
51. Bidwell GL 3rd, Raucher D. Enhancing the antiproliferative effect of topoisomerase II inhibitors using a polypeptide inhibitor of c-Myc. Biochem Pharmacol 2006;71:248-56.
52. Cohen DE, Prochownik EV. A functional hierarchy for c-Myc target genes? Lessons from MT-MC1. Cell Cycle 2006;5:392-3.
53. Anders CK, Acharya CR, Hsu DS, Broadwater G, Garman K,Foekens JA et al. Age-specific differences in oncogenic pathway deregulation seen in human breast tumors. PloS ONE 2008;3,e1373.
54. Berns EM, Klijn JG, van Putten WL, van Staveren IL, Portengen H, Foekens JA. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res 1992;52:1107-13.
55. Klijn JG, Berns EM, Foekens JA. Prognostic factors and response to therapy in breast cancer. Cancer Surv 1993;18:165-97.
56. Afify A, Bland KI, Mark HF. Fluorescent in situ hybridization assessment of chromosome 8 copy number in breast cancer. Breast Canc Res Treat 1996;32(2):201-8.
57. Gewirtz DA, Randolph JK, Chawla J, Orr MS, Fornari FA. Induction of DNA damage, inhibition of DNA synthesis and suppression of c-myc expression by the anthracycline analog, idarubicin (4-demethoxy-daunorubicin) in the MCF-7 breast tumor cell line. Cancer Chemother Pharmacol 1998;41:361-69.
58. Mark HF, Taylor W, Brown S, Samy M, Sun CL, Santoro K et al. Abnormal chromosome 8 copy number in stage I to stage IV breast cancer studied by fluorescence in situ hybridization. Cancer Genet Cytogenet 1999;108:1-5.
59. Aulmann S, Adler N, Rom J, Helmchen B, Schirmacher P, Sinn HP. et al: c-myc amplifications in primary breast carcinomas and their local recurrences. J Clin Pathol 2006;59:424-8.
60. Corzo C, Corominas JM, Tusquets I, Salido M, Bellet M, Fabregat X et al. The MYC oncogene in breast cancer progression: from benign epithelium to invasive carcinoma. Cancer Genet Cytogenet 2006;165:151-6.
61. Arango D, Corner GA, Wadler S, Catalano PJ, Augenlicht LH. c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo. Cancer Res 2001;61:4910-15.
62. Barratt PL, Seymour MT, Stenning SP, Georgiades I, Walker C, Birbeck K et al. DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet 2002;360:1381-91.
63. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007;109,25-32.
64. Hernández-Vargas H, Ballestar E, Carmona-Saez P, von Kobbe C, Bañón-Rodríguez I, Esteller M et al. Transcriptional profiling of MCF7 breast cancer cells in response to 5-Fluorouracil: relationship with cell cycle changes and apoptosis, and identification of novel targets of p53. Int J Cancer 2006; 119:1164-75.
65. www.linkos.cz.
66. Adjuvant Breast Cancer Trials Collaborative Group. Poly chemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial. JNCI 2007;99:506-15.